You can buy or sell Prothena and other stocks, options, ETFs, and crypto commission-free!
Prothena Corporation plc Ordinary Shares, also called Prothena, is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. Read More The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Dun Laoghaire, Dublin
52 Week High
52 Week Low
Yahoo FinanceMay 11
Here’s What Hedge Funds Think About Prothena Corporation plc
How do we determine whether Prothena Corporation plc (NASDAQ:PRTA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that their consensus long positions have historically outperformed the market when we adjust for known risk factors. Is Prothena Corporation plc (NASDAQ:PRTA) the right pick for your portfolio...
Yahoo FinanceMay 7
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 13.33% and -7.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Markets InsiderMay 7
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline Initiated cell line development of a lead candidate for preclinical tau program DUBLIN, Ireland, May 07, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the first quarter of 2019. In addition, the Company pr...
Expected Aug 6, After Hours